Related Experiment Video

Updated: Apr 30, 2026

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

13.1K

Rosiglitazone regulates anti-inflammation and growth inhibition via PTEN

Chiou-Feng Lin1, Kung-Chia Young2, Chyi-Huey Bai3

  • 1Institute of Clinical Medicine, National Cheng Kung University Medical College, Tainan 70101, Taiwan.

Biomed Research International
|April 24, 2014
PubMed

Insights

Rosiglitazone, a PPARγ agonist, reduces inflammation by regulating PTEN, independent of ROS inhibition. It also impacts PTEN-deficient cell growth, suggesting complex roles in cancer and inflammation pathways.

Area of Science:

  • Pharmacology
  • Molecular Biology
  • Immunology

Background:

  • Peroxisome proliferator-activated receptor gamma (PPARγ) agonists exhibit anti-inflammatory and anticancer effects.
  • The precise mechanisms of rosiglitazone's action via the phosphatase and tensin homolog (PTEN)-dependent pathway in inflammation and cancer are not fully understood.

Purpose of the Study:

  • To elucidate the role of the PTEN-dependent pathway in rosiglitazone's anti-inflammatory and anticancer effects.
  • To investigate how rosiglitazone modulates inflammatory mediators and cell growth in the context of PTEN expression.

Main Methods:

  • Utilized RAW 264.7 murine macrophages and PTEN knockdown (shPTEN) cells.
  • Assessed nitric oxide (NO), prostaglandin E2 (PGE2), and reactive oxygen species (ROS) production.
  • Analyzed Akt activation, p38 MAPK phosphorylation, and cell cycle progression (G1 arrest).
  • Stimulated cells with lipopolysaccharide (LPS) and treated with varying doses of rosiglitazone.

Main Results:

  • Low-dose rosiglitazone inhibited LPS-induced NO, PGE2, and Akt activation in macrophages, but not ROS production.
  • In shPTEN cells, rosiglitazone failed to inhibit LPS-induced NO, PGE2, and Akt activation, with elevated basal iNOS, COX-2, and ROS.
  • Higher doses of rosiglitazone inhibited p38 MAPK phosphorylation and ROS generation in shPTEN cells, independent of LPS.
  • Rosiglitazone induced G1 arrest and inhibited cell growth, affecting PTEN-deficient cells' reliance on ROS.

Conclusions:

  • Rosiglitazone's anti-inflammatory effects are linked to PTEN regulation, separate from ROS production inhibition.
  • Rosiglitazone influences the growth of PTEN-deficient cells, highlighting a complex interaction with ROS.
  • The study clarifies rosiglitazone's mechanisms in inflammation and cancer, emphasizing PTEN's crucial role.

More Related Videos

Isolation and Differentiation of Stromal Vascular Cells to Beige/Brite Cells07:22

Isolation and Differentiation of Stromal Vascular Cells to Beige/Brite Cells

Published on: March 28, 2013

38.4K
Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway07:15

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

Published on: August 23, 2024

1.1K

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.1K
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
993
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.3K
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.9K